| CEBRX | MEDEX | CEBRX / MEDEX | |
| Total Expense Ratio | 0.73 | 1.32 | 55% |
| Annual Report Gross Expense Ratio | 0.73 | 1.33 | 55% |
| Fund Existence | 14 years | 18 years | - |
| Gain YTD | 2.837 | 2.687 | 106% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | N/A | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 370M | 7.64B | 5% |
| Annual Yield % from dividends | 5.13 | 4.92 | 104% |
| Returns for 1 year | 10.21 | 9.83 | 104% |
| Returns for 3 years | 32.46 | 30.42 | 107% |
| Returns for 5 years | 13.78 | 12.17 | 113% |
| Returns for 10 years | 42.70 | 38.58 | 111% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MLVHX | 18.65 | 0.23 | +1.25% |
| MFS Low Volatility Equity I | |||
| ISCGX | 5.62 | -0.08 | -1.40% |
| Transamerica Small Cap Growth I | |||
| FKAIX | 53.28 | -0.89 | -1.64% |
| Federated Hermes Kaufmann Small Cap IS | |||
| VHIAX | 39.68 | -0.71 | -1.76% |
| JPMorgan Growth Advantage A | |||
| WFEMX | 23.55 | -0.54 | -2.24% |
| WCM Focused Emerging Markets Investor | |||